NanoViricides, Inc. (NYSE American: NNVC) reported financial results for its fiscal year ended June 30, 2026, and provided a corporate update that underscores significant clinical and regulatory progress for its broad-spectrum antiviral candidate, NV-387. The company, which is developing special purpose nanomaterials for antiviral therapy, received regulatory approval in the Democratic Republic of Congo to initiate Phase II trials evaluating NV-387 Oral Gummies for the treatment of Mpox and Ebola. Both trials began enrolling patients at the end of September 2026, marking a critical step in the drug's development.
In addition to the international trial approvals, NanoViricides received two key designations from the U.S. Food and Drug Administration for NV-387 as a treatment for measles: Orphan Drug Designation and Rare Pediatric Disease Drug designation. These designations could provide incentives such as market exclusivity and priority review, and they highlight the drug's potential to address serious unmet medical needs. The company's lead candidate, NV-387, is being developed as a treatment for a range of viral infections, including RSV, COVID, Long COVID, Influenza, MPOX/Smallpox, and Measles, demonstrating its broad-spectrum potential.
Financially, NanoViricides reported approximately $2.79 million in cash and cash equivalents as of June 30, 2026, up from approximately $1.67 million a year earlier. During fiscal 2026, the company raised approximately $9.01 million through registered direct and at-the-market equity offerings. Subsequently, in July 2026, it raised an additional approximately $3.8 million and stated it is pursuing further funding through grants, contracts, partnerships, and debt or equity financing. This improved cash position supports the company's ongoing clinical activities, though the path to drug development remains lengthy and capital-intensive.
The implications of these developments are substantial. The initiation of Phase II trials in Mpox and Ebola, combined with FDA designations for measles, positions NanoViricides to potentially address multiple high-priority viral threats with a single platform. The company's nanoviricide technology, licensed from TheraCour Pharma, Inc., is based on proprietary nanomaterials designed to attack viruses. If successful, NV-387 could become a versatile antiviral therapy, and the company's progress may attract additional investment and partnership interest. For investors, the latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. To view the full press release, visit https://ibn.fm/s000r.
NanoViricides' business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. The company holds broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles, and it is also developing drugs against oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The company's platform technology and programs are based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases.
MissionIR, a specialized communications platform, published the news break. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN, delivering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, visit MissionIR and www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
